Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR125543 dose-ranging trial in outpatients with major depressive disorder
NL-OMON34958Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crinecerfont in major depressive disorder (MDD) (5 arms), sponsored by Sanofi. Primary endpoint: Change from baseline to Day 56 in 17-item Hamilton Depression Rating Scale total score. Planned start Feb 2010; status: withdrawn.
02
Drugs
crinecerfont
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON34958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34958.